Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the researchers found that different CDK4/6 inhibitors used in treating HR+/HER2- advanced breast cancer have varying safety profiles and impacts on patient quality of life.

This study found that DEB-BACE combined with systemic chemotherapy was more effective than chemotherapy alone for unresectable lung squamous cell carcinoma, reducing side effects and improving survival rates.

In this study, researchers found that cepharanthine significantly inhibited the growth of non-small cell lung cancer cells by inducing apoptosis through ROS generation and altering multiple signaling pathways, suggesting potential as a novel lung cancer treatment.

In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.

This study found that estradiol significantly reduces cisplatin-induced cochlear hair cell death in mice, likely by activating Nrf2 and phase II detoxification enzymes.

This article discusses a unique case of permanent chemotherapy-induced alopecia in a patient receiving chemotherapy for breast cancer, characterized by a distinctive histologic finding and excludes bone marrow transplantation, but reports no new clinical results.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

This case report describes an unusual combination of hypertrichosis, androgenic alopecia, and trichomegaly in a patient with metastatic colon adenocarcinoma treated with cetuximab, with no adrenal or hormonal abnormalities detected.

This study found that the novel anti-HER2 antibody RC48 demonstrated promising activity and manageable safety in patients with HER2-overexpressing, advanced gastric or gastroesophageal junction cancer after at least two prior chemotherapy lines.

This study found that FOLFOX6 chemotherapy significantly decreased serum VEGF and CRP levels in advanced colorectal cancer patients, improved their quality of life as measured by KPS scores, and demonstrated a high overall therapeutic efficacy of 82.72% with manageable side effects.

This study found that several anti-cancer agents strongly inhibit DNA synthesis in human hair germinative cells, while certain cytokines showed only slight inhibition.

This study found that the PPARγ modulator NAC-GED-0507-Levo may protect hair follicles from chemotherapy-induced damage, potentially offering a strategy to address irreversible hair loss in cancer patients.

Endoxan often causes hair loss, which usually starts in the third week of treatment.

In this case report, a novel Ayurvedic preparation of Catharanthus roseus, used alongside conventional chemotherapy, was associated with tumor stability and improved general health in a patient with advanced esophageal squamous cell carcinoma.

This study found that N-acetylcysteine effectively prevented cyclophosphamide-induced alopecia in rats, and ImuVert plus N-acetylcysteine prevented alopecia from a cyclophosphamide-cytarabine combination.

This study found that doxorubicin induces hair follicle apoptosis through TRAIL receptor signaling, providing insights for managing chemotherapy-induced hair loss.

This article presents a rare case of cicatricial alopecia in a 59-year-old woman after using the epidermal growth factor receptor inhibitor gefitinib.

This review discusses the multiple severe side effects of cisplatin, carboplatin, and oxaliplatin in cancer treatment and reports no new clinical results; the authors emphasize the need for careful monitoring and supportive care to manage these effects.

This article reviews common skin reactions associated with epidermal growth factor receptor inhibitors and reports no new clinical findings, emphasizing the need for understanding nursing care and oncodermatology.

This article discusses dermatologic adverse events associated with topoisomerase inhibitors and anthracyclines, such as alopecia and hand-foot syndrome, but reports no new clinical results.

This study found that folliculin deficient renal cancer cells were more sensitive to irradiation due to increased autophagic cell death, suggesting a potentially enhanced therapeutic approach when combined with autophagy inducers like rapamycin.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

These guidelines discuss prevention and management strategies for dermatological toxicities but report no new clinical results; they include expert recommendations for conditions like acneiform rash and hand-foot syndrome.

This study found that patients, oncologists, and payers prioritize a significant improvement in efficacy to justify the added risks and costs when considering CDK4/6 inhibitors combined with endocrine therapy for early-stage breast cancer.

This article discusses the clinical manifestations and management strategies of skin side effects from epidermal growth factor receptor inhibitors, but reports no new clinical findings.

This study found that the combination of docetaxel, cisplatin, and 5-fluorouracil is active and feasible for treating squamous cell carcinoma of the head and neck, with dose level I recommended for further testing.

This article discusses safety, management, and adverse effects of chemotherapy in gynecological malignancies without reporting new clinical data, and emphasizes the importance of thorough patient and drug selection.

Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.

This case report describes two patients experiencing a bortezomib-induced skin eruption as multiple plaques on the trunk, with the lesions resolving spontaneously in about a week.